Insmed (NASDAQ: INSM) reported Q4 EPS of ($1.32), $0.14 worse than the analyst estimate of ($1.18). Revenue for the quarter came in at $104.44 million versus the consensus estimate of $97.68 million.

For earnings history and earnings-related data on Insmed (INSM) click here.